Abstract

BackgroundWe recently reported the clinical efficacy and safety of anti-TNF-alpha in a cohort of 15 rhupus patients with rheumatoid arthris and systemic lupus (“rhupus”). TNF-alpha and type I interferon (IFN)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Association of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 polymorphisms with systemic lupus erythematosus disease activity and biomarker levels
Bin Yang ... Qian Niu
Medicine | VOL. 99
Bin Yang, et. al.Bin Yang ... Qian Niu
28 Aug 2020
Association of IRF5 polymorphisms with activation of the interferon α pathway
Alice D C Hoftman ... Ornella J Rullo
Annals of the Rheumatic Diseases | VOL. 69
Alice D C Hoftman, et. al.Alice D C Hoftman ... Ornella J Rullo
23 Oct 2009
A loss‐of‐function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients
Damien Vitour ... Mustapha Si‐Tahar
EMBO Molecular Medicine | VOL. 3
Damien Vitour, et. al.Damien Vitour ... Mustapha Si‐Tahar
26 Jan 2011
Interleukin-10 as an explanation for pregnancy-induced flare in systemic lupus erythematosus and remission in rheumatoid arthritis.
M W Van Der Linden ... V Deneys-Laporte
Rheumatology (Oxford, England) | VOL. 38
M W Van Der Linden, et. al.M W Van Der Linden ... V Deneys-Laporte
01 Jun 1999
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers